225 related articles for article (PubMed ID: 8690798)
1. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia.
Lentz SR; Sobey CG; Piegors DJ; Bhopatkar MY; Faraci FM; Malinow MR; Heistad DD
J Clin Invest; 1996 Jul; 98(1):24-9. PubMed ID: 8690798
[TBL] [Abstract][Full Text] [Related]
2. Consequences of hyperhomocyst(e)inemia on vascular function in atherosclerotic monkeys.
Lentz SR; Malinow MR; Piegors DJ; Bhopatkar-Teredesai M; Faraci FM; Heistad DD
Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2930-4. PubMed ID: 9409278
[TBL] [Abstract][Full Text] [Related]
3. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia.
Böger RH; Bode-Böger SM; Sydow K; Heistad DD; Lentz SR
Arterioscler Thromb Vasc Biol; 2000 Jun; 20(6):1557-64. PubMed ID: 10845872
[TBL] [Abstract][Full Text] [Related]
4. Hyperhomocyst(e)inemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal disease.
Manns BJ; Burgess ED; Hyndman ME; Parsons HG; Schaefer JP; Scott-Douglas NW
Am J Kidney Dis; 1999 Oct; 34(4):669-77. PubMed ID: 10516348
[TBL] [Abstract][Full Text] [Related]
5. Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM.
Hofmann MA; Kohl B; Zumbach MS; Borcea V; Bierhaus A; Henkels M; Amiral J; Fiehn W; Ziegler R; Wahl P; Nawroth PP
Diabetes Care; 1997 Dec; 20(12):1880-6. PubMed ID: 9405911
[TBL] [Abstract][Full Text] [Related]
6. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans.
Tawakol A; Omland T; Gerhard M; Wu JT; Creager MA
Circulation; 1997 Mar; 95(5):1119-21. PubMed ID: 9054838
[TBL] [Abstract][Full Text] [Related]
7. Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM.
Hofmann MA; Kohl B; Zumbach MS; Borcea V; Bierhaus A; Henkels M; Amiral J; Schmidt AM; Fiehn W; Ziegler R; Wahl P; Nawroth PP
Diabetes Care; 1998 May; 21(5):841-8. PubMed ID: 9589252
[TBL] [Abstract][Full Text] [Related]
8. Asymmetric dimethyl-L-arginine (ADMA): a possible link between homocyst(e)ine and endothelial dysfunction.
Stühlinger MC; Stanger O
Curr Drug Metab; 2005 Feb; 6(1):3-14. PubMed ID: 15720202
[TBL] [Abstract][Full Text] [Related]
9. Vascular dysfunction in hyperhomocyst(e)inemia. Implications for atherothrombotic disease.
Stanger O; Weger M; Renner W; Konetschny R
Clin Chem Lab Med; 2001 Aug; 39(8):725-33. PubMed ID: 11592442
[TBL] [Abstract][Full Text] [Related]
10. Impaired anticoagulant response to infusion of thrombin in atherosclerotic monkeys associated with acquired defects in the protein C system.
Lentz SR; Fernández JA; Griffin JH; Piegors DJ; Erger RA; Malinow MR; Heistad DD
Arterioscler Thromb Vasc Biol; 1999 Jul; 19(7):1744-50. PubMed ID: 10397693
[TBL] [Abstract][Full Text] [Related]
11. Genetic and nongenetic factors for moderate hyperhomocyst(e)inemia.
Kang SS; Wong PW
Atherosclerosis; 1996 Jan; 119(2):135-8. PubMed ID: 8808490
[TBL] [Abstract][Full Text] [Related]
12. Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine.
Stühlinger MC; Oka RK; Graf EE; Schmölzer I; Upson BM; Kapoor O; Szuba A; Malinow MR; Wascher TC; Pachinger O; Cooke JP
Circulation; 2003 Aug; 108(8):933-8. PubMed ID: 12912818
[TBL] [Abstract][Full Text] [Related]
13. ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins.
Sydow K; Schwedhelm E; Arakawa N; Bode-Böger SM; Tsikas D; Hornig B; Frölich JC; Böger RH
Cardiovasc Res; 2003 Jan; 57(1):244-52. PubMed ID: 12504835
[TBL] [Abstract][Full Text] [Related]
14. Hyperhomocyst(e)inemia in renal transplant recipients with and without cyclosporine.
Ducloux D; Fournier V; Rebibou JM; Bresson-Vautrin C; Gibey R; Chalopin JM
Clin Nephrol; 1998 Apr; 49(4):232-5. PubMed ID: 9582553
[TBL] [Abstract][Full Text] [Related]
15. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans.
Kanani PM; Sinkey CA; Browning RL; Allaman M; Knapp HR; Haynes WG
Circulation; 1999 Sep; 100(11):1161-8. PubMed ID: 10484535
[TBL] [Abstract][Full Text] [Related]
16. Causes and consequences of hyperhomocyst(e)inemia.
Pietrzik K; Brönstrup A
Int J Vitam Nutr Res; 1997; 67(5):389-95. PubMed ID: 9350483
[TBL] [Abstract][Full Text] [Related]
17. [Hyperhomocyst(e)inemia--an independent risk factor of stroke].
Lalouschek W; Aull S; Deecke L; Schnider P; Uhl F; Zeiler K
Fortschr Neurol Psychiatr; 1996 Jul; 64(7):271-7. PubMed ID: 8765893
[TBL] [Abstract][Full Text] [Related]
18. Pathogenicity of thermolabile methylenetetrahydrofolate reductase for vascular dementia.
Yoo JH; Choi GD; Kang SS
Arterioscler Thromb Vasc Biol; 2000 Aug; 20(8):1921-5. PubMed ID: 10938012
[TBL] [Abstract][Full Text] [Related]
19. Hyperhomocyst(e)inemia and MTHFR C677T genotypes in patients with central retinal vein occlusion.
Weger M; Stanger O; Deutschmann H; Temmel W; Renner W; Schmut O; Semmelrock J; Haas A
Graefes Arch Clin Exp Ophthalmol; 2002 Apr; 240(4):286-90. PubMed ID: 11981642
[TBL] [Abstract][Full Text] [Related]
20. Hyperhomocyst(e)inemia induces multiorgan damage.
Miller A; Mujumdar V; Shek E; Guillot J; Angelo M; Palmer L; Tyagi SC
Heart Vessels; 2000; 15(3):135-43. PubMed ID: 11289502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
